Will the Biden administration undermine cutting-edge industries in Texas?
Will the Biden administration undermine cutting-edge industries in Texas? Read More »
Fact Check: Proposed FTC Rule to Ban Non-Competes Will Hamper Innovation
Claim: President Biden recently lauded the Federal Trade Commission’s (FTC) proposal to ban all non-compete agreements — which prevent employees who leave jobs from working for rival firms for a period of time — as a positive step taken to “restore the dignity of work.” He claimed that, under the current agreements, “a cashier at
Fact Check: Proposed FTC Rule to Ban Non-Competes Will Hamper Innovation Read More »
C4IP Co-Sponsors 118th Congress Welcome Reception, featuring the Creative Rights Caucus
On February 28th, 2023, the Council for Innovation Promotion and nearly 50 other pro-innovation organizations co-sponsored a Welcome Reception for the 118th Congress, featuring the Creative Rights Caucus. Distinguished guests included Representatives Jamaal Bowman (D-NY), Lloyd Doggett (D-TX), Josh Gottheimer (D-NJ), Darrell Issa (R-CA), Kevin Kiley (R-CA), and actor Harry Hamlin. House Co-Chairs of the
C4IP Co-Sponsors 118th Congress Welcome Reception, featuring the Creative Rights Caucus Read More »
Strong IP Rights are Needed to Protect the Next Stevie Wonder, Mary J. Blige
This year’s star-studded GRAMMY Awards featured extraordinary performances by Stevie Wonder, Smokey Robinson, Missy Elliott, Mary J. Blige, Jay-Z, and more. Their groundbreaking careers and presence on the stage are reminders that the journey to superstardom is not easy. According to the Recording Industry Association of America, it can cost $2 million to break an
Strong IP Rights are Needed to Protect the Next Stevie Wonder, Mary J. Blige Read More »
America’s patent system isn’t broken — so it doesn’t need “fixing”
Dr. Rachel Goode, an executive at a German generic pharmaceutical company, recently argued that “brand-name drug companies are gaming the [U.S.] patent system” by filing duplicative patents meant to block generics manufacturers from entering the market with cheaper copy-cat treatments. But there’s scant evidence to support that claim. Brand-name drugmakers file patents at a rate
America’s patent system isn’t broken — so it doesn’t need “fixing” Read More »
